<DOC>
	<DOCNO>NCT01774721</DOCNO>
	<brief_summary>This multinational , multicenter , randomize , open-labeled , Phase 3 study compare efficacy safety treatment Dacomitinib ( PF-00299804 ) treatment gefitinib patient locally advanced metastatic non-small cell lung cancer , epidermal growth factor receptor ( EGFR ) activate mutation ( ) . Analyses primary objective ( Progression Free Survival ) do define protocol .</brief_summary>
	<brief_title>ARCHER-1050 : A Study Dacomitinib vs. Gefitinib 1st-Line Treatment Of Advanced NSCLC .</brief_title>
	<detailed_description>440 patient randomize 1:1 ratio Dacomitinib ( PF-00299804 ) vs. gefitinib .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Evidence histo cytopathology confirm , advance NSCLC ( know histology ) presence EGFR activate mutation ( exon 19 deletion L858R mutation exon 21 ) . It acceptable subject presence exon 20 T790M mutation together either EGFR activate mutation ( exon 19 deletion L858R mutation exon 21 ) include study Minimum 12 month disease free interval completion systemic therapy recurrence NSCLC Adequate tissue sample must available central analysis . Adequate renal , hematologic , liver function . ECOG PS 01 . Radiologically measurable disease . Any evidence mixed histology include element small cell carcinoid lung cancer . Any mutation exon 19 deletion L858R exon 21 , without presence exon 20 T790M mutation . Any history brain mets leptomeningeal mets . Any previous anticancer systemic treatment early , locally advanced , metastatic NSCLC . Uncontrolled medical disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>first-line</keyword>
	<keyword>locally advanced metastatic</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>EGFR</keyword>
	<keyword>Archer</keyword>
	<keyword>mutation</keyword>
	<keyword>dacomitinib</keyword>
	<keyword>SFJ</keyword>
	<keyword>PF-00299804</keyword>
</DOC>